Review of NICE's recommendations, 1999-2005
BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7552.1266 (Published 25 May 2006) Cite this as: BMJ 2006;332:1266Data supplement
Published as supplied by the author
Table A.1
Summary of classification of NICE guidances, 1999-2005
NICE ID
DISEASE/CONDITION
Health Technology
‘Yes, can or should be used’
Yes,
Minor
Restrictions
Yes,
Major restrictions
No, due to lack of evidence or poor cost effectiveness
1
Wisdom teeth
Prophylactic removal
X
2
Primary total hip replacement
Hip prostheses
x
3
Ovarian cancer, recurrent (resistant)
Paclitaxel
x
4
Ischaemic heart disease
Coronary artery stents
x
5
Cervical smear tests
Liquid based cytology
X
6
Breast cancer
Paclitaxel/docetaxel
X
7
Dyspepsia
Proton pump inhibitors
x
8
Hearing
Hearing aid technology
X
9
Type 2 diabetes mellitus
Rosiglitazone
X
10
Asthma, under 5s
Inhaler systems
x
11
Arrhythmias
Implantable cardioverter defibrillators
x
12
Acute coronary syndromes: medical management
Glycoprotein Iib/iiia inhibitors
x
12
Acute coronary syndromes – adjunct to percutaneous coronary intervention (PCI)
Glycoprotein Iib/iiia inhibitors
x
13
Attention deficit hyperactivity disorder in childhood
Methylphenidate
x
14
Hepatitis C
Ribavarin and interferon alpha combination therapy
x
15
Influenza
Zanamivir, at-risk adults
x
15
Influenza
Zanamivir, healthy adults
X
16
Knee joint defects
Autologues cartilage transplantation
X
17
Colorectal cancer
Laparoscopic surgery
X
18
Inguinal hernia, recurrent and bilateral
Laparoscopic surgery
x
18
Inguinal hernia, primary
Laparoscopic surgery
X
19
Alzheimer's disease
Donepezil/rivastigmine/ galantamine
x
20
Motor neurone disease
Riluzole
X
21
Type 2 diabetes melitus
Pioglitazone
X
22
Obesity
Orlistat
x
23
Brain cancer, recurrent
Temozolomide
x
24
Wound care
Debriding agents
X
25
Pancreatic cancer
Gemcitabine
x
26
Lung cancer, non-small cell
First line (paclitaxel, gemcitabine, vinorelbine)
X
26
Lung cancer, non-small cell
Docetaxel, 2nd line
x
27
Rheumatoid arthritis/osteoarthritis
Meloxicam, etodolac, rofecoxib, celecoxib
x
28
Ovarian cancer, advanced
Topotecan
X
29
Lymphocytic leukaemia, B-cell chronic
Fludarabine
X
30
Breast cancer, advanced
Docetaxel, 1st line
x
30
Breast cancer, advanced
Paclitaxel, docetaxel, 2nd line
x
31
Obesity
Sibutramine
x
32
Multiple sclerosis
Beta interferon, glatimer
X
33
Colorectal cancer, advanced
Irinotecan, 2nd line monotherapy
X
33
Colorectal cancer, advanced
Irinotecan, 1st line use in combination therapy
X
33
Colorectal cancer, advanced
Oxaliplatin, 1st line
x
33
Colorectal cancer, advanced
Raltitrexed
X
34
Breast cancer, advanced
Trastuzumab
X
35
Juvenile idiopathic arthritis
Etanercept
X
36
Rheumatoid arthritis
Infliximab, etanercept
X
37
Lymphoma, follicular non-Hodgkin's
Rituximab, 3rd or subsequent line
x
38
Asthma, older children
Inhaler devices
x
39
Smoking cessation
Bupropion
X
39
Smoking cessation
Nicotine replacement therapy
X
40
Crohn's disease- severe active
Infliximab
X
Crohn's disease- fistulising
Infliximab
X
41
Pregnancy, rhesus negative women
Routine anti-D prophylaxis
X
42
Growth hormone deficiency - children,
Somatropin
X
43
Schizophrenia
Amisulpride, Olanzapine, quetiapine, risperidone, zotepine
x
43
Schizophrenia
Clozapine
x
44
Hip resurfacing
Metal on metal
x
45
Ovarian cancer, advanced
Pegylated liposomal doxorubicin hydrochloride (PLDH)
X
46
Obesity
Surgical treatments
x
47
Acute coronary syndromes- medical management
Glycoprotein iib/iiia inhibitors
x
47
Acute coronary syndromes- adjunct to PCI
Glycoprotein iib/iiia inhibitors
X
48
Renal (ESRD)
Home haemodialysis
X
49
Central venous catheters
2-D imaging ultrasound guidance device
X
49
Central venous catheters
Audio-guided Doppler ultrasound guidance device
X
50
Leukaemia, chronic myeloid--chronic phase, 2nd line therapy
Imatinib
X
50
Leukaemia, chronic myeloid--accelerated phase
Imatinib
X
50
Leukaemia, chronic myeloid--blast phase
Imatinib
X
51
Depression and anxiety
Computerised cognitive behaviour therapy
X
52
Acute myocardial infarction, early thrombolysis
Alteplase, reteplase, tenecteplase. Streptokinase
X
53
Diabetes, type 2
Insulin glargine,
X
53
Diabetes, type 1
Insulin glargine
X
54
Breast cancer, advanced- 1st line
Vinorelbine
x
54
Breast cancer, advanced – 2nd line
Vinorelbine
X
55
Ovarian cancer
Paclitaxel
X
56
Stress incontinence
Tension-free vaginal tape (Gynecare TVT)
x
57
Diabetes
Continuos subcutaneous insulin infusion
x
58
Influenza
Zanamivir, oseltamivir in at risk adults
X
58
Influenza
Zanamivir, Oseltamivir in healthy adults
X
58
Influenza
Amantadine: at risk or healthy adults
X
59
Severe depressive illness, catatonia, prolonged or severe manic episode
Electroconvulsive therapy (ECT)
x
59
Schizophrenia: schizophrenia
Electroconvulsive therapy (ECT)
X
60
Diabetes
Patient education models
x
61
Colorectal cancer, metastatic
Capecitabine, tegafur with uracil
x
62
Breast cancer, advanced or metastatic
Capecitabine, plus docetaxel
X
62
Breast cancer, advanced or metastatic
Capecitabine monotherapy, 2nd line
X
63
Diabetes, type 2
Combination therapy with glitazones
x
64
Growth hormone deficiency: adults
Somatropin
X
65
Agressive inon-Hodgkin’s lymphoma
Rituximab
X
66
Bipolar I disorder, acute mania
Valproate semisodium, olanzapine
X
67
Influenza, seasonal prophylaxis,
Oseltamivir
X
67
Influenza, post-exposure
Oseltamivir
x
67
Influenza, seasonal prophylaxis
Amantadine
X
67
Influenza, post-exposure
Amantadine
X
68
Age-related macular degeneration, classic with no occult CNV
Photodynamic therapy
x
68
Age-related macular degeneration, predominantly classic CNV
Photodynamic therapy
X
69
Cervical screening
Liquid-based cytology
x
70
Chronic myeloid leukaemia (chronic, accelerate and blast)
Imatinib
x
71
Coronary heart disease (angina or MI)
Bare-metal stent
x
71
Coronary heart disease (angina or MI)
Drug eluting stent
x
72
Rheumatoid arthritis
Anakinra
X
73
Coronary artery disease
MPS with SPECT,
X
74
Trauma
Pre-hospital fluid replacement therapy
x
75
Chronic hepatitis C
Peginterferon alfa and ribavirin – combination therapy
X
75
Chronic hepatitis C
Peginterferon alfa - monotherpay
X
76
Epilepsy in adults
Newer drugs
X
77
Insomnia
Zaleplon, zolpidem, zopiclone
X
78
Heavy menstrual bleeding
Fluid filled balloon, microwave ablation
X
79
Epilepsy - children
Newer drugs
X
80
Acute coronary syndromes (NSTEMI)
Clodipogrel
X
81
Atopic eczema
Topical corticosteroids
X
82
Atopic eczema
Tacrolimus
X
82
Atopic eczema
Pimecrolimus
X
83
Inguinal hernia repair
Laparoscopic surgery
X
84
Severe sepsis
Drotrecogin
X
85
Immunosuppressive therapy post renal transplantation
Induction therapy (basiliximab, daclizumab)
X
85
Immunosuppressive therapy post renal transplantation
Tacrolimus in triple therapy
X
85
Immunosuppressive therapy post renal transplantation
MMF in triple therapy
X
85
Immunosuppressive therapy post renal transplantation
Sirolimus in triple therapy
X
86
Gastro intestinal stromal tumours (GIST)
Imatinib
X
Notes
- The 86 topics refer to the guidances on health technologies issued by NICE between April 1999 and April 2005.
- Each topic was subdivided by the number of recommendations made by NICE. Where a single recommendation applied to a group of technologies or patient sub-groups, this was treated as separate sub-topic.
- The classification of each sub-topic was the made initially by James Raftery. The following experts then commented on the classification, leading to some small changes. The help of the following experts is acknowledged: Amanda Burls, Andy Clegg, Rumona Dickson, Ruairidh Milne, Alec Miners, Mark Sculpher, Ken Stein, Rod Taylor, Tom Walley.
Related articles
- Correction Published: 13 July 2006; BMJ 333 doi:10.1136/bmj.333.7559.137-c
- Education And Debate Published: 01 December 2001; BMJ 323 doi:10.1136/bmj.323.7324.1300
- Paper Published: 06 January 2005; BMJ 330 doi:10.1136/bmj.38285.482350.82
- PAPERS Published: 15 December 2004; BMJ doi:10.1136/bmj.38285.482350.82
- Analysis And Comment Published: 25 May 2006; BMJ 332 doi:10.1136/bmj.332.7552.1268
See more
- Communicating risk to patients in the emergency departmentBMJ December 05, 2016, 355 i6437; DOI: https://doi.org/10.1136/bmj.i6437
- Biological treatment is approved for severe eosinophilic asthmaBMJ December 01, 2016, 355 i6472; DOI: https://doi.org/10.1136/bmj.i6472
- Patient care is at risk from lack of new funds in autumn statement, healthcare leaders warnBMJ November 24, 2016, 355 i6356; DOI: https://doi.org/10.1136/bmj.i6356
- Government must be clearer in its claims about NHS funding, says statistics watchdogBMJ November 24, 2016, 355 i6340; DOI: https://doi.org/10.1136/bmj.i6340
- US must address addiction as an illness, not as a moral failing, Surgeon General saysBMJ November 22, 2016, 355 i6265; DOI: https://doi.org/10.1136/bmj.i6265
Cited by...
- Neurologic Therapeutics in 2035: The Neurology Future Forecasting Series
- NICE is dead; long live NICE
- NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium
- The author's response:
- NICE work: Nice try
- How NICE may be outflanked